Buy Tesamorelin – Peptide Partners

Product Overview & Specifications

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog investigated for its role in GHRH receptor activation, metabolic stability, and hepatic transcriptomic modulation in preclinical research. Peptide Partners supplies this research-grade material for in-vitro testing, laboratory experimentation, receptor pharmacology, structural biology, and analytical method development.

Published studies have examined tesamorelin using immunoaffinity purification coupled with LC-HRMS/MS detection, cryo-electron microscopy structural analyses of GHRHR-Gs complexes, hepatic transcriptomic profiling, proteomic analysis, and anti-doping analytical protocols. Research areas include GHRH receptor binding, Gs protein coupling mechanisms, transmembrane domain interactions, hepatic gene expression modulation, inflammatory pathway regulation, and metabolic stability characterization.

The product name supplied for this listing is “Tesamorelin.” Researchers should verify the exact identity, sequence, formulation, and batch-specific certificate of analysis before beginning any experiment. Findings from published tesamorelin studies should not be assumed to apply to every commercial batch or formulation.

Product Specifications

Specification	Details
Product name	Tesamorelin
Compound type	Synthetic growth hormone-releasing hormone (GHRH) analog
Primary molecular targets	Growth hormone-releasing hormone receptor (GHRHR), stimulatory G protein (Gs)
Primary research areas	GHRHR activation, Gs protein coupling, receptor-ligand structural interactions, hepatic transcriptomics, inflammatory pathway modulation, analytical detection methods, and anti-doping analysis
Product format	10 mg vials
Vial size	10 mg
Vial capacity	3 mL
Available box combinations	20 mg, 50 mg, 100 mg, and 200 mg
Multi-vial purity	99.81%
Independent testing	Yes
Endotoxin screening	Passed
Heavy-metals screening	Passed
Purity screening	Passed
Manufacturer ID	WF03
Batch ID	TES202605
Cost per milligram	$4.49–$6.10

The stated 99.81% purity is based on multi-vial testing. Researchers should review the batch-specific certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

Qualitative Identification of Growth Hormone-Releasing Hormones in Human Plasma by Means of Immunoaffinity Purification and LC-HRMS/MS

Authors: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, and Thevis M

Publication: Drug Testing and Analysis, 2016

PMCID: PMC4830873

Reference: View publication

This study reports the development and validation of a qualitative method for the simultaneous detection of four GHRHs, including Tesamorelin, in human plasma. The method employs immunoaffinity purification using a polyclonal GHRH antibody followed by nano-ultrahigh performance liquid chromatography-high resolution/high accuracy tandem mass spectrometry (LC-HRMS/MS).

The in vitro experiments demonstrated the metabolic stability of Tesamorelin. The method was validated for specificity, linearity, recovery, lower limit of detection, imprecision, and ion suppression/enhancement effects, proving its fitness for purpose in sports drug testing. The research provides a robust analytical framework for detecting GHRH analogs in biological matrices.

The findings establish that tesamorelin exhibits metabolic stability in vitro, facilitating its detection in plasma samples. The validated LC-HRMS/MS method enables sensitive, specific identification of tesamorelin and related GHRH compounds for forensic and anti-doping applications.

Plain-English Research Summary

Researchers developed a highly sensitive method to detect Tesamorelin and other growth hormone-releasing hormones (GHRHs) in human plasma. This new test uses a combination of immunoaffinity purification and liquid chromatography-mass spectrometry to identify these substances with high accuracy. The study also investigated the stability of Tesamorelin in a laboratory setting and found it to be metabolically stable. This is significant for anti-doping applications as it provides a reliable method for detecting the use of these banned substances in athletes.

Structural Basis for Activation of the Growth Hormone-Releasing Hormone Receptor

Authors: Zhou F, Li JJ, Li XC, Jiang Y, Yang DH, Chen LN, Xu HE, Li MJ, and Li XF

Publication: Nature Communications, 2020

DOI: 10.1038/s41467-020-18945-0

Reference: View publication

This study elucidates the cryo-electron microscopy structure of the human growth hormone-releasing hormone receptor (GHRHR) in complex with its endogenous ligand GHRH and the stimulatory G protein (Gs). The structure reveals that GHRH binds to a novel site within the transmembrane domain of the receptor, which is distinct from the binding mode of other class B GPCRs.

The study identifies key residues for GHRH binding and receptor activation, providing a structural basis for understanding the mechanism of action of GHRH and its analogues like Tesamorelin. The structural information reveals the molecular determinants of receptor-ligand recognition and Gs protein coupling.

The findings provide a structural framework for understanding how GHRH analogs activate the GHRHR. This knowledge supports rational design of new therapeutic agents targeting the GHRHR and provides mechanistic insights into class B GPCR activation.

Plain-English Research Summary

Scientists have created a 3D map of the receptor in our bodies that Tesamorelin and other similar hormones bind to. This map, obtained using a technique called cryo-electron microscopy, shows exactly how the hormone ‘docks’ with the receptor to activate it. This is a crucial discovery because it helps us understand the fundamental mechanism of how Tesamorelin works at a molecular level. This knowledge can be used to design new and better drugs that target this receptor for various medical conditions.

Effects of Tesamorelin on Hepatic Transcriptomic Signatures in HIV-Associated NAFLD

Authors: Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, and Grinspoon SK

Publication: JCI Insight, 2021

DOI: 10.1172/jci.insight.140134

Reference: View publication

This study investigated the effects of Tesamorelin on hepatic transcriptomic and proteomic signatures in patients with HIV-associated non-alcoholic fatty liver disease (NAFLD). The researchers performed RNA sequencing on liver biopsies and proteomic analysis of plasma samples from patients treated with Tesamorelin or placebo.

The results showed that Tesamorelin treatment was associated with downregulation of hepatic gene sets involved in inflammation, tissue repair, and cell division. Furthermore, a targeted proteomic analysis revealed that Tesamorelin modulated the levels of several plasma proteins that are linked to these pathways. These findings provide a molecular basis for the observed clinical benefits of Tesamorelin in reducing liver fat and fibrosis in this patient population.

The research demonstrates that tesamorelin influences hepatic gene expression patterns related to inflammatory and fibrotic pathways. The transcriptomic and proteomic data provide mechanistic insights into how GHRH analogs modulate liver metabolism and tissue remodeling.

Plain-English Research Summary

In this study, researchers investigated how Tesamorelin affects the liver in people with HIV-associated fatty liver disease. They analyzed liver tissue and blood samples from patients treated with Tesamorelin and found that the drug changed the activity of genes involved in inflammation, tissue repair, and cell division. Specifically, Tesamorelin reduced the activity of genes that cause inflammation and scarring in the liver. This study provides important insights into the molecular mechanisms by which Tesamorelin improves liver health in this patient population.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, growth hormone treatment, liver treatment, HIV treatment, anti-doping evasion compound, diagnostic material, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.